Source:http://linkedlifedata.com/resource/pubmed/id/12356379
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0010068,
umls-concept:C0015663,
umls-concept:C0023820,
umls-concept:C0030705,
umls-concept:C0286651,
umls-concept:C0376674,
umls-concept:C0445604,
umls-concept:C0681850,
umls-concept:C1280500,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2587213,
umls-concept:C2697811
|
pubmed:issue |
7
|
pubmed:dateCreated |
2002-10-1
|
pubmed:abstractText |
The effects of atorvastatin at 20, 40, and 80 mg/day on plasma lipoprotein subclasses were examined in a randomized, placebo-controlled fashion over 24 weeks in 103 patients in the fasting state who had coronary heart disease (CHD) with low-density lipoprotein (LDL) cholesterol levels >130 mg/dl. The effects of placebo and atorvastatin 40 mg/day were examined in 88 subjects with CHD in the fasting state and 4 hours after a meal rich in saturated fat and cholesterol. These findings were compared with results in 88 age- and gender-matched control subjects. Treatment at the 20, 40, and 80 mg/day dose levels resulted in LDL cholesterol reductions of 38%, 46%, and 52% (all p <0.0001), triglyceride reductions of 22%, 26%, and 30% (all p <0.0001), and high-density lipoprotein (HDL) cholesterol increases of 6%, 5%, and 3%, respectively (all p <0.05 at the 20- and 40-mg doses). The lowest total cholesterol/HDL cholesterol ratio was observed with the 80 mg/day dose of atorvastatin (p <0.0001 vs placebo). Remnant-like particle (RLP) cholesterol decreased 33%, 34%, and 32%, respectively (all p <0.0001). Lipoprotein(a) [Lp(a)] cholesterol decreased 9%, 16%, and 21% (all p <0.0001), although Lp(a) mass increased 9%, 8%, and 10%, respectively (all p <0.01). In the fed state, atorvastatin 40 mg/day normalized direct LDL cholesterol (29% below controls), triglycerides (8% above controls), and RLP cholesterol (10% below controls), with similar reductions in the fasting state. At this same dose level, atorvastatin treatment resulted in 39%, 35%, and 59% decreases in fasting triglyceride in large, medium, and small very LDLs, as well as 45%, 33%, and 47% reductions in cholesterol in large, medium, and small LDL, respectively, as assessed by nuclear magnetic resonance (all significant, p <0.05), normalizing these particles versus controls (77 cases vs 77 controls). Moreover, cholesterol in large HDL was increased 37% (p <0.001) by this treatment. Our data indicate that atorvastatin treatment normalizes levels of all classes of triglyceride-rich lipoproteins and LDL in both the fasting and fed states in patients with CHD compared with control subjects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Dietary Fats,
http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoprotein(a),
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
90
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
689-96
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12356379-Anticholesteremic Agents,
pubmed-meshheading:12356379-Cholesterol,
pubmed-meshheading:12356379-Cholesterol, HDL,
pubmed-meshheading:12356379-Cholesterol, LDL,
pubmed-meshheading:12356379-Coronary Disease,
pubmed-meshheading:12356379-Dietary Fats,
pubmed-meshheading:12356379-Dose-Response Relationship, Drug,
pubmed-meshheading:12356379-Fasting,
pubmed-meshheading:12356379-Female,
pubmed-meshheading:12356379-Heptanoic Acids,
pubmed-meshheading:12356379-Humans,
pubmed-meshheading:12356379-Lipoprotein(a),
pubmed-meshheading:12356379-Lipoproteins,
pubmed-meshheading:12356379-Male,
pubmed-meshheading:12356379-Middle Aged,
pubmed-meshheading:12356379-Postprandial Period,
pubmed-meshheading:12356379-Pyrroles,
pubmed-meshheading:12356379-Treatment Outcome,
pubmed-meshheading:12356379-Triglycerides
|
pubmed:year |
2002
|
pubmed:articleTitle |
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
|
pubmed:affiliation |
Atherosclerosis Research Laboratory, Lipid and Heart Disease Prevention Clinic, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. eschaefer@hnrc.tufts.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|